iRhythm initiated with a Buy at BofA on market and margin expansion

As previously reported, BofA initiated coverage of iRhythm (IRTC) with a Buy rating and $200 price target The Zio wireless patch-based sensor is “best in class” for long term continuous monitoring of electrocardiogram data to diagnose arrhythmias, the analyst tells investors. The firm, which sees share gain potential in the mobile cardiac telemetry segment of the market, also notes that the company is driving market expansion with primary care physicians and asymptomatic patients and is at a turning point in EBITDA profitability.